Show simple item record

dc.contributor.authorChilcott, Robert
dc.contributor.authorLarner, Joanne
dc.contributor.authorMatar, Hazem
dc.contributor.authorKansagra, Sneha
dc.contributor.authorTheivendran, Baveetharan
dc.contributor.authorViegas, Vanessa Ann
dc.contributor.authorGoldman, Virginia Streusand
dc.date.accessioned2016-04-06T08:56:03Z
dc.date.available2016-04-06T08:56:03Z
dc.date.issued2015
dc.identifier.citationChilcott , R , Larner , J , Matar , H , Kansagra , S , Theivendran , B , Viegas , V A & Goldman , V S 2015 , ' Optimisation of a dosing regime for a topical skin protectant (barrier cream) ' , Cutaneous and Ocular Toxicology , vol. 34 , no. 4 , pp. 327-334 . https://doi.org/10.3109/15569527.2014.994124
dc.identifier.issn1556-9527
dc.identifier.otherPURE: 8716246
dc.identifier.otherPURE UUID: 42942ce1-3602-461b-a63b-03a8022fd386
dc.identifier.otherPubMed: 25597377
dc.identifier.otherScopus: 84946059656
dc.identifier.urihttp://hdl.handle.net/2299/16956
dc.description.abstractContext: Topical skin protectants (barrier creams) have the potential to reduce or enhance the severity of dermal lesions following exposure to allergens or irritants. Therefore, it is essential that such products are subject to appropriate clinical evaluation prior to marketing. Consequently, it is important to accurately define a dosing regime in order to assess test products under appropriate conditions. Objective: In this study, we extended the use of a standard rubefacient (methyl nicotinate; MN) assay to establish the optimum thickness and duration of action of a novel barrier cream (RD1433). White petroleum jelly (Vaseline®) was used as a comparator product. Methods: The dermal response to MN was measured on the volar forearm skin of volunteers (n = 12; average age 47.5 years) using an array of biophysical instruments and visual scoring. When applied at a nominal thickness of 0.1 mm, RD1433 retained effectiveness against MN for up to six hours. In contrast, Vaseline® was relatively ineffective. Moreover, RD1433 provoked no measurable signs of irritation and so can be considered acceptable for further clinical evaluation. Conclusion: Future clinical studies using RD1433 should be based on topical application of a 0.1 mm thickness layer every six hours.en
dc.format.extent8
dc.language.isoeng
dc.relation.ispartofCutaneous and Ocular Toxicology
dc.titleOptimisation of a dosing regime for a topical skin protectant (barrier cream)en
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionPharmaceutics
dc.contributor.institutionToxicology
dc.description.statusPeer reviewed
rioxxterms.versionofrecordhttps://doi.org/10.3109/15569527.2014.994124
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record